Lupin Ltd., of Mumbai, India, named Theresa Stevens chief corporate development officer for its global operations, with full responsibility for global merger and acquisitions and specialty business strategy. Read More
Shanghai Fosun Pharmaceutical (Group) Co. Ltd., of China, is acquiring Chindex International Inc., of Bethesda, Md., a health care company providing services in China through the operations of United Family Healthcare, a network of private primary care hospitals and affiliated ambulatory clinics. Read More
TAIPEI, Taiwan – Taiwan Liposome Co. (TLC) and Ablynx NV are planning to jointly develop a new drug delivery technology combining TLC's immunoliposome platform with Ablynx' antibody-derived nanobody technology that will enable more precisely targeted delivery of liposome-encapsulated cytotoxic compounds to disease sites in cancer patients. Read More
HONG KONG – The CFDA gave the green light to Chongqing Zhifei Biological Products Co. Ltd. (SZ:300122) to launch its joint vaccine against group A and C meningococcus and haemophilus influenzae type B (AC-Hib). Zhifei's subsidiary, Beijing Zhifei Lvzhu Biopharmaceutical Co., developed the vaccine that aims to prevent infectious diseases such as meningitis, pneumonia, septicemia, cellulitis, arthritis and epiglottitis caused by group A and C meningococcus as well as type b haemophilus influenzae (Hib). Read More
HONG KONG – A Chinese investment company focused on health care has secured a third fund to invest $188 million in pharmaceuticals, medical technology, health care services and biotech companies. Read More
SHANGHAI – At the 4th Annual Biopharma China Congress in Shanghai last week, smaller biotechs and established contract research organizations (CRO) rubbed shoulders with government-funded academics. Meanwhile the China division of Sanofi SA of France was one of the only international companies in attendance. Read More
SHANGHAI – Betta Pharmaceuticals Co. Ltd. (Betta Pharma), with the first small molecule anticancer drug in China, is aiming to go public in China later this year. Read More
